ESRX Express Scripts Inc

  • STOCK
  • ESRX
  • Price as of: Dec 02, 02:51 PM EST
  • $75.91
  • +$0.08
  • +0.1%
  • Industry
  • Health care plans
Share

ESRX Stock Dividend Data

Add ESRX to Watchlist
  • Dividend Yield
    0.00% Healthcare Average 1.04%
  • Annualized Payout
    $0.00  
  • Payout Ratio
    0.0% EPS $6.39
  • Dividend Growth
    No Payout Increase Last Year
  • Get ESRX DARS™ Rating

Looking to buy or sell ESRX?

Buy Now
Sell Now
Upcoming Dividend Payouts

ESRX Upcoming Dividend Payouts

ESRX has not yet officially announced its next dividend payout.
DARS Rating™ Breakdown

Dividend.com DARS Rating™ Breakdown for ESRX

Metric Ranking Avg Ranking Notes
Stock not rated.
Yield History

ESRX Dividend Yield & Stock Price History

Dividend Payout History

ESRX Dividend Payout History

No Payout History Is Available

Brought to You by Mitre Media

Growth History

ESRX Dividend Growth History

Annualized Growth
1994-2012
Annualized Growth
1994-2004
Annualized Growth
2004-2008
Annualized Growth
2008-2012
Annualized Growth
Last 5 Yrs
Annualized Growth
Last 3 Yrs
Annual
Growth
2012
Consecutive
Years of
Increases
Reveal More Dividend Growth History for ESRX
Historical Annual Dividend Data & Growth

ESRX Historical Annual Dividend Data & Growth

Payout Amount Calendar Year Annual Growth
No Payout History Is Available
Historical Dividend Data

ESRX Dividend History

Payout Amount Declared Date Ex-Dividend Date Record Date Pay Date ▼ Qualified Dividend? Payout Type Frequency
No Payout History Is Available

Knowledge Centers

Company Profile

ESRX Company Profile

Exchange: NASDAQ
Sector: Healthcare
Industry: Health Care Plans

High Yield Stocks

High Yield Stocks

Looking for dividend stocks with great yields? Visit our list of:

High Yield Dividend Stocks
News

Express Scripts Inc News

  • Express Scripts Price Target Raised by Merrill Lynch/Bank of America (ESRX)

    Pharmacy benefit manager Express Scripts, Inc. (ESRX) saw its price target raised on Friday by analysts at Merrill Lynch/Bank of America. Merrill/BoA raised its price target for ESRX to $80, citing expectations that the company will be abe to meet its targets on its acquisition of benefit manager NextRx. Express Scripts shares closed Thursday at $68.59. Merrill Lynch/Bank of America maintained its "Buy" rating on the stock. Express Scripts shares fell 20 cents, or -0.3%, in afternoon trading Friday. The Bottom Line Shares of ESRX are off 52-week highs of $77 a share. The stock has technical support in the $58-60 price area. If the shares can continue the recent momentum, we see overhead resistance around the $70-73 price levels. We do not currently rate this non-dividend paying stock, but we do follow this pharmacy benefits play closely. Express Scripts, Inc. (ESRX) does not currently pay a dividend. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • It will be quite an interesting day today after seeing the fund managers scamper after winners yesterday with a big buying frenzy. Lots of earnings...
  • Express Scripts Upgraded by Merrill Lynch/Bank of America (ESRX)

    Express Scripts, Inc. (ESRX) was upgrade to a "Buy" Friday by Merrill Lynch/Bank of America. The two financial analysts set a price target of $78 for ESRX. The pharmacy benefits company's shares closed Thursday at $62.29. Merrill and Bank of America also raised their earnings estimates for ESRX, citing income from the company's purchase of WellPoint's NextRx unit. Express Scripts said back on April 13th that it would buy pharmacy benefits manager NextRx for $4.86 billion. Express Scripts shares fell 31 cents, or -0.5%, in morning trading Friday. The Bottom Line Shares of ESRX are off 52-week highs of $77 a share. The stock has technical support in the $54-59 price area. If the shares can firm up, we see overhead resistance around the $65-67 price levels near-term. We do not currently rate this non-dividend paying stock at this time, but we do follow this pharmacy benefits play closely. Express Scripts, Inc. (ESRX) does not currently pay a dividend. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • Today's trading session will be dominated by the street's reaction to this morning's jobs report. Regardless of those results, the key names and...
  • Express Scripts Selling 23 Million Shares to Fund NextRx Acquisition (ESRX)

    Pharmacy benefit management company Express Scripts, Inc. (ESRX) said Tuesday that it has begun a 23 million-share offering in order to help fund its acquisition of WellPoint's (WLP) NextRx unit. Express said it expects to net $1.6 billion to $1.8 billion from the offering. The funds will be used to convert the NextRx acquisition into an all-cash deal. Previously, the deal was comprised of cash and stock. Express Scripts announced it would buy WellPoint's NextRx unit in a $4.68 billion deal back in April. Once completed, Express will become the second-largest pharmacy benefits company in the U.S. The acquisition is expected to close in the third or fourth quarter this year. Express Scripts shares fell 28 cents, or -0.4%, in morning trading Tuesday. The Bottom Line Shares of ESRX are off 52-week highs of $77 a share. The stock has technical support in the $54-59 price area. If the shares can firm up, we see overhead resistance around the $65-67 price levels near-term. We do not currently rate this non-dividend paying stock at this time, but we do follow this pharmacy benefits play closely. Express Scripts, Inc. (ESRX) does not currently pay a dividend. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • Stock futures are indicated lower as we are hearing of more stock offerings from managements that understand the liquidity window will not stay...
  • Pharmacy benefit management company Express Scripts () will buy health insurer WellPoint's () NetRx prescription division for $4.86...
  • As we said in our earlier e-mail we sent out, it would have been really bad news for the market to not be able to rally the day after President...